AstraZeneca PLC 
Description
AstraZeneca Plc.(Stock Ticker: AZN) is a global pharmaceutical company focused on the discovery, development and commercialization of prescription medicines across oncology, cardiovascular, renal and metabolic diseases, and rare diseases.
Therapeutic Areas 
Oncology
Cardiovascular
Respiratory & Immunology
Renal and Metabolism
Infectious Diseases
Rare Diseases
Three Main Products-
Explore three key products shaping the company’s portfolio.
1-Biggest Revenue Generator
TAGRISSO 
Osimertinib mesylate
Oncology · NSCLC · Oral · Approved
| INDICATION | BIOMARKER | ROUTE |
|---|---|---|
1 Metastatic EGFR T790M-positive NSCLC 2 Locally advanced, unresectable Stage III NSCLC (cannot be surgically removed) following chemoradiation | EGFR T790M EGFR exon 19 deletion / exon 21 L858R | Oral Oral |
| Active Ingredient | Osimertinib mesylate |
|---|---|
| Dosage Form | Tablet |
| Strengths | 40 mg, 80 mg |
| Clinical Stage | Approved |
US FDA | Approved 2015 |
EU/EMA | Approved 2016 |
| REGULATORY APPROVAL | DATE |
|---|---|
| U.S. FDA | 13 November 2015 |
| EU | 1 February 2016 |
Commercial Intelligence (Q2 2026 SALES)
US Sales | EU Sales | Emerging Markets |
|---|---|---|
$845M | $383M | $512M |
2-Fastest Growing Product
Tezspire 
Tezepelumab-Ekko
Respiratory & Immunology · Severe Asthma · Subcutaneous · Approved
| INDICATION | TARGET | ROUTE |
|---|---|---|
| 1 Severe asthma 2 Severe chronic rhinosinusitis with nasal polyps (CRSwNP) | TSLP (Thymic stromal lymphopoietin) | Subcutaneous injection |
| Active Ingredient | Tezepelumab-Ekko |
|---|---|
| Dosage Form | Solution for injection |
| Strengths | 210 mg |
| Clinical Stage | Approved |
| U.S. FDA | Approved · 2021 |
| EU / EMA | Approved · 2022, 2025 |
| REGULATORY APPROVAL | DATE |
|---|---|
U.S. FDA — Severe asthma | 17 December 2021 |
EU — Severe asthma | 19 September 2022 |
EU — CRSwNP indication | 22 October 2025 |
Commercial Intelligence (Q2 2026 SALES)
US Sales(Amgen) | EU Sales | Emerging Markets |
|---|---|---|
$486M | $107M | $24M |
3-Newly Approved / Key New Product
BAXFENDY 
Baxdrostat
Cardiovascular, Renal & Metabolism · Hypertension · Oral · Newly Approved
| INDICATION | TARGET | ROUTE |
|---|---|---|
| Hypertension | Aldosterone synthase (CYP11B2) | Oral |
| Active Ingredient | Baxdrostat |
|---|---|
Dosage Form | Tablet |
Strengths | 1 mg , 2mg |
| Drug Class | Aldosterone synthase inhibitor |
| Clinical Stage | Approved |
U.S FDA | Approved 15 May 2026 |
| Clinical Program | BaxHTN Phase III |
Commercial Intelligence (Q2 2026 SALES)
US Sales | Emerging Markets |
|---|---|
$2M | $1M |
Description
A global biotechnology company focused on developing and delivering innovative therapies across neurology, and rare diseases.
Therapeutic Areas
Neuroscience / Neurology
Immunology
Rare Diseases
Three Main Products-
Explore three key products shaping the company’s portfolio.
1-Biggest Revenue Generator
TYSABRI 
Natalizumab
Neuroscience · Multiple Sclerosis · Intravenous · Approved
| INDICATION | TARGET | ROUTE |
|---|---|---|
| Multiple Sclerosis (MS) | α4-integrin (α4β1 integrin) | Intravenous infusion |
| Active Ingredient | Natalizumab |
|---|---|
| Dosage Form | Injection / Intravenous infusion |
| Strengths | 300 mg |
| Clinical Stage | Approved |
| U.S. FDA | Approved |
| EU / EMA | Approved as ASPAVELI |
| REGULATORY APPROVAL | DATE |
|---|---|
| U.S. FDA Approval | 23 November 2004 |
| EU / EMA Approval | 27 June 2006 |
Commercial Intelligence (Q2 2026 SALES)
US Sales | Rest of World |
|---|---|
$270.5M | $180.3M |
2-Fastest Growing Product
EMPAVELI 
Pegcetacoplan
Rare Disease · Paroxysmal Nocturnal Hemoglobinuria · Subcutaneous · Approved
| INDICATION | TARGET | ROUTE |
|---|---|---|
| Paroxysmal Nocturnal Hemoglobinuria (PNH) | Complement C3 | Subcutaneous |
| Active Ingredient | Pegcetacoplan |
|---|---|
| Dosage Form | Injection for subcutaneous use |
| Strengths | 1,080 mg/20 mL (54 mg/mL) |
| Clinical Stage | Approved |
| U.S. FDA | Approved |
| EU / EMA | Approved |
Commercial Intelligence (Q2 2026 SALES)
US Sales $30.4M |
|---|
EMPAVELI® — Commercial & Ownership History
- Apellis Pharmaceuticals — Original developer and U.S. commercial company for EMPAVELI.
↓ - Biogen — Acquired Apellis Pharmaceuticals in May 2026, bringing EMPAVELI into Biogen’s Growth Portfolio and taking over its U.S. business.
↓ - Sobi — Holds the ex-U.S. commercialization rights for systemic pegcetacoplan, including Europe.
↓ - Europe — Marketed as ASPAVELI® by Sobi.
- EU sales: Not separately disclosed by Sobi.
Q2 2026 Approval Note: No new molecular entity/product received its first U.S. FDA approval by Biogen in Q2 2026. The major 2026 approval milestones were for existing products, including SPINRAZA’s high-dose regimen and LEQEMBI IQLIK’s subcutaneous formulation.